Includes technologies from the cell and gene therapy space, including NK cells, stem cells, T cells, AAV, Adenovirus, CRISPR, DNA, Lentivirus, RNA and vaccinia.
Scientists from University of Pittsburgh have developed a novel approach to target cancer cells through the insertion of a “suicide gene” (HSV1-tk) into key gene fusion areas of the cancer genome.
University of Pittsburgh researchers have developed an innovative approach to enhance the effectiveness of adoptive cell therapy for cancer treatment by redirecting glucose metabolism.
University of Pittsburgh researchers have developed a novel approach for isolating and expanding tumor-infiltrating γδ T cells (TILs) from solid tumors, presenting a significant advancement in immunotherapy.
University of Pittsburgh researchers have isolated genes encoding two unique T cell receptors (TCRs) capable of recognizing peptide epitopes from mutated proteins found in many cancers.
Immunotherapy is uniquely positioned to shift the paradigm of cancer treatment. Cancer cells evade immune destruction in part by generating an immunosuppressive microenvironment.
The absence of regulatory T cells (Treg) is a hallmark for a wide variety of disorders, including autoimmune disorders, dermatitis, periodontitis, and transplant rejection.
Epidermal Growth Factor Receptor (EGFR) has emerged as a promising molecular target for the treatment of Head and neck squamous cell carcinoma (HNSCC).